Pharmafile Logo

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

July 13, 2023 | Market Access 

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum’s Deep Dive.

- PMLiVEWith the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers of these exciting, in theory, one-shot personalised therapies.

I have a vivid memory of watching War in the Blood, a 2019 feature-length BBC documentary about CAR-T cell therapy and the potentially revolutionary impact on the landscape of cancer treatment. The filmmakers followed two leukaemia patients in first-in-human trials in the UK. CAR-T was showcased as their only hope and a way to re-programme the immune system to kill cancers. As with any clinical trial, questions arose. In this case, key questions centred around the long-term safety and effectiveness of the personalised CAR-T, due to its potential curative intent.

As more CAR-Ts have obtained marketing authorisation in the intervening years, similar questions have also been on the minds of payers and policymakers making decisions about how – and in which patient populations – to pay for this new modality, whose upfront cost and theoretically one-time administration is difficult to assess in the same way as traditional drugs.

In this article for pharmaphorum’s Oncology Deep Dive, Research Partnership reviews the market access opportunities and challenges encountered by CAR-Ts commercialised in the EU-4 and the UK (see Tables 1 and 2). To complement our review, we reached out to 12 payers in our network with advanced therapy expertise from across the UK, France, Germany, Spain, and Italy. We discuss their feedback and the ramifications below. We also share select findings from our new syndicated tool Access CGT, a cell and gene therapy analogue access and policy tracker.

Find out more here

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

First, we need to talk: mental healthcare in the MENA region

In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

ESOMAR Asia Pacific 2018

13-15 May, Bangkok

Intellus Worldwide Summit 2018

Visit us on stand number 413

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Conducting market research for scientific publication guide

Conducting and using market research for publication can be valuable for shaping opinions in healthcare. The findings can be used to influence existing perceptions, change current practices and behaviour in...

Therapy Watch appoints new Associate Director

Research Partnership has appointed Mark Hollis to join the Therapy Watch team as Associate Director. Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA...

Sabera Hyderally appointed Head of MedTech North America

Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.